Alitretinoin是一种能激活所有已知的细胞内维甲酸类受体亚型（RARα、RARβ、RARγ、RXRα、RXRβ和RXRγ）的内源性维甲酸。2009年11月加拿大批准Toctino（alitretinoin，阿利维A酸）软胶囊上市，每日一次，每次30mg，用于局部外用强效糖皮质激素无效的慢性手部湿疹患者。0．1%阿利维A酸凝胶剂（商品名：Panretin）已于1999年被批准用于治疗皮肤卡波济肉瘤.

通用名称为PANRETIN
alitretinoin 0.1％;凝胶。

法律分类：
RX

药理类为PANRETIN
维甲酸。

对PANRETIN制造商
卫材制药

主治为PANRETIN
皮损与艾滋病有关的卡波济氏肉瘤（堪萨斯州）。

成人剂量为PANRETIN
申请到病变（避免粘膜和正常皮肤），每日两次;不阻挡;可能会增加3-4倍，每天容忍。降低频率或暂停治疗，如果出现局部毒性。

儿童剂量为PANRETIN
不推荐使用。

为PANRETIN警告/注意事项
不使用时，全身金水治疗需要。避免阳光，紫外线光。易燃。 （Cat.D）怀孕，哺乳母亲：不推荐。

为PANRETIN的相互作用
避蚊胺的毒性增加（避免）。

为PANRETIN不良反应
光敏性，皮疹，瘙痒，疼痛，剥脱性皮炎，感觉异常，水肿。

PANRETIN如何提供？
凝胶60G

相关疾病：
卡波西氏肉瘤

-------------------------------------------------------
Panretin® (alitretinoin) gel 0.1%
Panretin® (alitretinoin) gel is a prescription medicine that is applied to the skin for the treatment of skin lesions in patients with AIDS-related Kaposi's sarcoma (KS). Panretin gel should not be used when systemic (oral or injectable) anti-KS therapy is required (e.g. more than 10 new KS lesions in the prior month, symptomatic lymphedema [swelling in tissues], symptomatic pulmonary KS [affecting the lungs], or symptomatic visceral involvement [affecting internal organs]). There is no experience to date using Panretin gel with systemic anti-KS treatment.

Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose and throat or in other organs. In the United States, approximately 1.21 men per 100,000, in 2007, were diagnosed with Karposi's sarcoma.

Important Safety Information

Panretin gel is not indicated in patients with a known hypersensitivity to retinoids or to any of the ingredients of the product.

Pregnancy Category D - Panretin gel could cause fetal harm if significant absorption were to occur in a pregnant woman. If Panretin gel is used during pregnancy, or if the patient becomes pregnant while taking it, the patient should be made aware of the potential harm to the fetus. Women of child-bearing potential should be advised to avoid becoming pregnant. Because of the potential for adverse reactions from Panretin gel in nursing infants, mothers should discontinue nursing prior to using the drug.

Patients with cutaneous T-cell lymphoma were less tolerant of Panretin gel; 5 of 7 patients had 6 episodes of treatment limiting toxicities - grade 3 dermal irritation - with Panretin gel (0.01 or 0.05%).

Patients should minimize exposure of treated areas to sunlight and sunlamps during the use of Panretin gel. Patients should not use products that contain DEET (N,N-diethyl-m-toluamide), a common ingredient of insect repellant products, while using Panretin gel.

The safety of Panretin gel was assessed in clinical studies of 385 patients with AIDS-related KS. Adverse events associated with the use of Panretin occurred almost exclusively at the gel application site. Dermal toxicity begins with erythema, with continued application of Panretin gel, erythema may increase and edema may develop. Dermal toxicity may become treatment limiting with intense erythema, edema, and vesiculation. Usually adverse events were mild to moderate to in severity and led to withdrawal from the study in 7% of the patients. Severe local (application site) skin adverse events occurred in about 10% of patients.

The most common adverse events with an incidence of at least 10% at the application site in Panretin gel-treated patients were; rash, pain, pruritus, and paraesthesia.

Please also see the Panretin Gel Full Prescribing Information.

Patients should consult their healthcare provider if they have any questions about, or are experiencing any side effects from, this product.

For more information about Panretin gel call Eisai Medical Services Oncology (877) 873-4724. To report suspected adverse reactions, call (877) 873-4724.

For more information on assistance with prescription drug costs that may be available to patients, call the Eisai Assistance Program at (866) 613-4724.

Panretin is a registered trademark of Eisai Inc.

CORP50